Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

<u id="h96tt"><rp id="h96tt"></rp></u>

<ul id="h96tt"></ul>

<abbr id="h96tt"><button id="h96tt"></button></abbr>

<pre id="h96tt"><strike id="h96tt"></strike></pre>

<strong id="h96tt"></strong>

You are here: Industry Insights > Market News > Janssen's Stelara shows promise across two dosages in ulcerative colitis

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu

tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu

Ste-Glu-AEEA-AEEA-OSU

Ste-Glu-AEEA-AEEA-OSU

C20-OtBu-Glu(OtBu)-AEEA-AEEA-OH

C20-OtBu-Glu(OtBu)-AEEA-AEEA-OH

Entecavir hydrate

Entecavir hydrate

Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH

Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH

5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-amine

5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-amine

Janssen's Stelara shows promise across two dosages in ulcerative colitis

pharmafileNovember 20, 2018

Tag: Janssen , Stelara , IBDQ

Favorites

Previous:Menlo Therapeutics' cough drug fails to meet primary endpoint in phase II trial

Next:New hospital-led organisation aims to tackle drug pricing problem by manufacturing generic drugs

Related News

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

PRNewswireAugust 21, 2025

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise.

Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning

PRNewswireAugust 20, 2025

NUZ-001 OLE Study Demonstrates Long-Term Safety and Efficacy Signals

Biotech NewswireAugust 20, 2025

Janssen's Stelara shows promise across two dosages in ulcerative colitis | Pharmasources.com

Lepu Biopharma (2157.HK) announces 2025 interim results

ACN NewswireAugust 21, 2025

Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025.

You may like
More>>

PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM

LINCOMYCIN HCL

GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides

CEFALEXINE cephalosporins

CEFALEXINE cephalosporins

CEFRADINE cephalosporins

CEFRADINE cephalosporins

CEFADROXIL cephalosporins

CEFADROXIL cephalosporins

CEFIXIME cephalosporins

CEFIXIME cephalosporins

CEFATHIAMIDINE cephalosporins

CEFATHIAMIDINE cephalosporins

CEFMINOX SODIUM cephalosporins

CEFMINOX SODIUM cephalosporins

CEFOXITIN SODIUM cephalosporins

CEFOXITIN SODIUM cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

About Us: About PharmaSources; Terms of Service; Privacy Policy; Event Data Sharing Notice; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Copyright 2006-2025 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 滬ICP備05034851號(hào)-182 滬公網(wǎng)安備31010402010101號(hào)
Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight July 2025

PharmaSources Customer Service

<strike id="umyrd"></strike>